Injecting, sexual risk behaviors and HIV infection in young cocaine and heroin users in Spain project itinere group

European Addiction Research

Volumn 15, Issue 3, 2009, Pages 171-178

  Brugal, M Teresa ^a,b   Pulido, José ^c   Toro, Carlos ^d   De La Fuente, Luis ^b,c,e   Bravo, María J ^b   Ballesta, Rosario ^g   Soriano, Vicente ^d   Barrio, Gregorio ^b,f   Vallejo, Fernando ^b,c   Domingo Salvany, Antonia ^a,b   Castellano, Yolanda ^a  

^a HOSPITAL DEL MAR   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c CARLOS III INSTITUTE OF HEALTH   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e MINISTERIO DE SANIDAD Y CONSUMO   (Spain)

^f UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^g Fundacion Andaluza para la Atencion a Las Drogodependencias e Incorporacion Social   (Spain)

Author keywords

Cocaine; Heroin; Injecting risk behaviors; Sexual risk behaviors

Indexed keywords

ADULT; ARTICLE; BLOOD ANALYSIS; COCAINE DEPENDENCE; DRUG USE; EVALUATION; FEMALE; HEPATITIS B; HEPATITIS C; HEROIN DEPENDENCE; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SEXUALITY; SOCIAL STATUS; SPAIN; SUBSTANCE ABUSE; SYRINGE;

EID: 66449123699     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000220345     Document Type: Article

References (44)

1. European Centre for Disease Prevention and Control: HIV infection in Europe: 25 years into the pandemic. Stockholm, European Centre for Disease Prevention and Control, 2007. http://www.eu2007.de/en/News/ download-docs/Maerz/ 0312-BSGV/ 040Background.pdf.
2. de la Fuente L, Barrio G, Royuela L, Bravo MJ: The transition from injecting to smoking heroin in three Spanish cities. The Spanish Group for the Study of the Route of Heroin Administration. Addiction 1997; 92: 1749-1763.
3. de la Fuente L, Bravo MJ, Toro C, Brugal MT, Barrio G, Soriano V, Vallejo F, Ballesta R: Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes. J Epidemiol Community Health 2006;60:537-542.
4. European Monitoring Center for Drugs and Drug Addiction (EMCDDA): Annual report 2008: the state of the drugs problem in Europe. Luxembourg, Office for Official Public Trends of the European Communities, 2008. http://www.emcdda. europa.eu/attache- ments.cfm/att-64227-EN-EMCDDA- AR08-en.pdf.
5. United Nations Office on Drugs and Crime (UNODC): Annual report. Vienna, United Nations, 2007. http://www.unodc.org/pdf/ annual-report-2007/AR06- fullreport.pdf.
6. de la Fuente L, Brugal MT, Domingo-Salva- ny A, Bravo MJ, Neira-Leon M, Barrio G: Mäs de treinta anos de drogas ilegales en Espana: una amarga historia con algunos con- sejos para el futuro. Rev Esp Salud Publica 2006;80:505-520.
7. Tyndall M, Currie SL, Spittal P, Li K, Wood E, O'Shaughnessy MV, Schechter MT: Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic.AIDS 2003;17: 887-893.
8. Delegación del Gobierno para el Plan Nacio- nal sobre Drogas: Observatorio Espanol so- bre Drogas, Informe 2004. Madrid, Ministe- rio de Sanidad y Consumo, 2005. http://www. pnsd.msc.es/Categoria2/publica/pdf/oed- 2004.pdf.
9. de la Fuente L, Bravo MJ, Barrio G, Parras F, Suarez M, Rodes A, Noguer I: Lessons from the history of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic among Spanish drug injectors. Clin Infect Dis 2003; 37:S410-S415.
10. de la Fuente L, Brugal MT, Ballesta R, Barrio G, Bravo MJ, Domingo-Salvany A, Silva TC, Ambros M, Grupo del Proyecto Itinere: Me- todologia del estudio de cohortes del proyec- to Itinere sobre consumidores de heroina en tres ciudades espanolas y caracteristicas bäsicas de los participantes. Rev Esp Salud Publica 2005; 79: 475-491.
11. Vallejo F, Toro C, de la Fuente L, Brugal MT, Barrio G, Soriano V, Ballesta R, Bravo MJ: Hepatitis B vaccination: an unmet challenge in the era of harm reduction programs. J Subst Abuse Treat 2007; 34:398-406.
12. Bieleman B, Díaz A, Merlo G, Kaplan C: Lines across Europe: Nature and Extent of Cocaine Use in Barcelona, Rotterdam and Turin. Amsterdam, Swets & Zeitlinger, 1993.
13. Heckathorn DD: Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl 1997;44:174-199.
14. Watters JK, Biernacki P: Targeted sampling: options for the study of hidden populations. Soc Probl 1989; 36:416-430.
15. Pulido J, Brugal MT, de la Fuente L, Ballesta R, Barrio G, Bravo MJ, Domingo-Salvany A, Castellano Y, Fernandez F, Grupo del Proyec- to Itinere: Metodologia de reclutamiento y caracteristicas de una cohorte de jövenes consumidores habituales de cocaina de tres ciudades espanolas (Proyecto Itinere-cocai- na). Gac Sanit 2009, Epub ahead of print.
16. Des Jarlais DC, Paone D, Milliken J, Turner CF, Miller H, Gribble J, Shi Q, Hagan H, Friedman SR: Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet 1999;353:1657-1661.
17. Newman JC, Des Jarlais DC, Turner CF, Gribble J, Cooley P, Paone D: The differential effects of face-to-face and computer interview modes. Am J Public Health 2002;92: 294-297.
18. Turner CF, Ku L, Rogers SM, Lindberg LD, Pleck JH, Sonenstein FL: Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. Science 1998;280:867-873.
19. Questionnaire Development System 2.0 (QDS™). Bethesda, NOVA Research Company, 2002.
20. Organización Panamericana de la Salud: Encuesta de comportamiento en CODAR: Herramientas ba&́sicas. Cuaderno 1. Diseño del estudio, adaptación del cuestionario e indicadores. Washington, Organización Panamericana de la Salud, 2008. http:// www.ops-oms.org/ Spanish/AD/FCH/AI/ Codar-cuaderno1.pdf.
21. Bravo MJ: Infecciones de transmisiön san- guinea o sexual entre las personas que se inyectan drogas y sus parejas en las Americas: manual para profesionales de la salud. Washington, Organizaciön Panamericana de la Salud, 2004. http://www.paho.org/ spanish/ad/fch/ai/InfecUDI.pdf.
22. Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D: Correlates of HIV infection among young adult short-term injection drug users. AIDS 2000;14:717-726.
23. Kozlov AP, Shaboltas AV, Toussova OV, Ve-revochkin SV, Masse BR, Perdue T, Beau-champ G, Sheldon W, Miller WC, Heimer R,Ryder RW, Hoffman IF: HIV incidence and factors associated with HIV acquisition among injection drug users in St Petersburg,Russia. AIDS 2006; 20:901-906.
24. Patrick DM, Tyndall M, Cornelisse PG, Li K, Sherlock CH, Rekart ML, Strathdee SA, Cur- rie SL, Schechter MT, O'Shaughnessy MV: Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 2001; 165: 889-895.
25. Castilla J, Lorenzo JM, Izquierdo A, Lezaun ME, Lopez I, Moreno-Iribas C, Nunez D, Perucha M, R'kaina LC, Zulaika D: Carac- teristicas y tendencias de los nuevos diag- nösticos de infecciön por el virus de la inmu- nodeficiencia humana (2000-2004). GacSanit 2006; 20:442-448.
26. Bluthenthal RN, Kral AH, Gee L, Lorvick J, Moore L, Seal K, Edlin BR: Trends in HIV seroprevalence and risk among gay and bisexual men who inject drugs in San Francisco, 1988 to 2000. J Acquir Immune Defic Syndr 2001; 28:264-269.
27. Judd A, Hickman M, Jones S, McDonald T, Parry JV, Stimson GV, Hall AJ: Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective co-hort study. BMJ 2005; 330: 24-25.
28. Shafer KP, Hahn JA, Lum PJ, Ochoa K, Graves A, Moss A: Prevalence and correlates of HIV infection among young injection drug users in San Francisco. J Acquir Immune Defic Syndr 2002; 31: 422-431.
29. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, Celentano DD, Solomon L, Polk BF: The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991; 109: 75-100.
30. Fischer B, Rehm J, Brissette S, Brochu S, Bru- neau J, El-Guebaly N, Noel L, Tyndall M, Wild C, Mun P, Baliunas D: Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health 2005;82: 250-266.
31. Fischer B, Rehm J, Patra J, Kalousek K, Hay-don E, Tyndall M, El-Guebaly N: Crack across Canada: comparing crack users and crack non-users in a Canadian multi-city co hort of illicit opioid users. Addiction 2006;101: 1760-1770.
32. Gyarmathy VA, Neaigus A, Miller M, Friedman SR, Des Jarlais DC: Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users. J Acquir Immune Defic Syndr 2002; 30: 448-456.
33. Howe CJ, Fuller CM, Ompad DC, Galea S, Koblin B, Thomas D, Vlahov D: Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non- injecting drug users in New York City. Drug Alcohol Depend 2005; 79: 389-395.
34. Kaye S, Darke S: Non-fatal cocaine overdose among injecting and non-injecting cocaine users in Sydney, Australia. Addiction 2004;99:1315-1322.
35. Kaye S, Darke S: Injecting and non-injecting cocaine use in Sydney, Australia: physical and psychological morbidity. Drug Alcohol Rev 2004;23: 391-398.
36. Neaigus A, Miller M, Friedman SR, Des Jar- lais DC: Sexual transmission risk among noninjecting heroin users infected with human immunodeficiency virus or hepatitis C virus. J Infect Dis 2001; 184:359-363.
37. Prinzleve M, Haasen C, Zurhold H, Matali JL, Bruguera E, Gerevich J, Bacskai E, Ryder N, Butler S, Manning V, Gossop M, Pezous AM, Verster A, Camposeragna A, Anders- son P: Cocaine use in Europe - a multi-centre study: patterns of use in different groups.Eur Addict Res 2004; 10: 147-155.
38. Shearer J, Johnston J, Fry CL, Kaye S, Dillon P, Dietze P, Collins L: Contemporary cocaine use patterns and associated harms in Melbourne and Sydney, Australia. Drug Alcohol Rev 2007;26:537-543.
39. Instituto Nacional de Estadistica y Ministe- rio de Sanidad y Consumo: Encuesta de salud y häbitos sexuales 2003, informe general. Madrid, Instituto Nacional de Esta- distica, 2006. http://www.ine.es/prodyser/ pubweb/saludyhs03/saludyhs03.htm.
40. Des Jarlais DC, Arasteh K, Perlis T, Ha- gan H, Abdul-Quader A, Heckathorn DD, McKnight C, Bramson H, Nemeth C, Torian LV, Friedman SR: Convergence of HIV sero- prevalence among injecting and non-injecting drug users in New York City. AIDS 2007;21: 231-235.
41. Neaigus A, Gyarmathy VA, Zhao M, Miller M, Friedman SR, Des Jarlais DC: Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. J Infect Dis 2007; 195:1052-1061.
42. Scheinmann R, Hagan H, Lelutiu-Weinber- ger C, Stern R, Des Jarlais DC, Flom PL, Strauss S: Non-injection drug use and hepatitis C virus: a systematic review. Drug Alcohol Depend 2007; 89:1-12.
43. Darke S: Self-report among injecting drug users: a review. Drug Alcohol Depend 1998;51: 253-263.
44. McElrath K, Chitwood DD, Griffin DK, Comerford M: The consistency of self-reported HIV risk behavior among injection drug users. Am J Public Health 1994; 84: 1965-1970.